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Abstract
Wilms tumors (WT) have provided broad insights into the interface between development and tumorigenesis. Fur-
ther understanding is confounded by their genetic, histologic, and clinical heterogeneity, the basis of which remains
largely unknown. We evaluated 224WT for global gene expression patterns;WT1, CTNNB1, andWTXmutation; and
11p15 copy number and methylation patterns. Five subsets were identified showing distinct differences in their
pathologic and clinical features: these findings were validated in 100 additional WT. The gene expression pattern
of each subset was compared with published gene expression profiles during normal renal development. A novel
subset of epithelial WT in infants lacked WT1, CTNNB1, and WTX mutations and nephrogenic rests and displayed
a gene expression pattern of the postinduction nephron, and none recurred. Three subsets were characterized by a
low expression of WT1 and intralobar nephrogenic rests. These differed in their frequency of WT1 and CTNNB1
mutations, in their age, in their relapse rate, and in their expression similarities with the intermediate mesoderm
versus the metanephric mesenchyme. The largest subset was characterized by biallelic methylation of the imprint
control region 1, a gene expression profile of the metanephric mesenchyme, and both interlunar and perilobar
Abbreviations: WT, Wilms tumor; ICR1, imprint control region 1; ICR2, imprint control region 2; MM, metanephric mesenchyme; LOI, loss of imprinting; LOH, loss of
heterozygosity; ROI, retention of imprinting; UPD, uniparental disomy
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nephrogenic rests. These data provide a biologic explanation for the clinical and pathologic heterogeneity seen
within WT and enable the future development of subset-specific therapeutic strategies. Further, these data support
a revision of the current model of WT ontogeny, which allows for an interplay between the type of initiating event
and the developmental stage in which it occurs.
Neoplasia (2012) 14, 742–756
Introduction
The initiation and progression of the most common adult cancers
result from a stepwise accumulation of multiple genetic events within
a finite number of pathways occurring over many years. In contrast,
the initiation of neoplasia in children results from one to two genetic
events that occur over the course of months rather than years. These
events usually involve genes responsible for normal development and
result in tumors that closely resemble cells within the developing
embryo. They are also often the same genetic events that participate
in the development of adult tumors. Therefore, pediatric embryonal
neoplasms provide invaluable insights into normal development and
into both adult and childhood neoplasia. The investigation of Wilms
tumor (WT), one of the most common tumors of childhood, is a re-
markable illustration of this. This unique success is due in part to the
fact that WT is the only embryonal neoplasm that arises within pre-
cursor lesions known as nephrogenic rests, of which there are two pre-
dominant types: perilobar and intralobar [1]. WTs are also capable of
showing a striking spectrum of appearances ranging from undifferen-
tiated “blastemal” tumors to “teratoid” tumors composed of a mixture
of differentiated skeletal muscle, chondroid, and a variety of epithelial
cell types. This heterogeneity implies a complexity to the underlying
causes of WT that has fascinated investigators for decades.
Two genetic loci have consistently been associated with the patho-
genesis of WT, theWT1 gene at 11p13, and the WT2 locus at 11p15.
WT1 encodes a transcription factor important in multiple phases of
normal renal, gonadal, and cardiac development [2,3]. Germline muta-
tions of WT1 result in syndromes, including Denys-Drash and Wilms
tumor-aniridia-genitourinary malformation-mental retardation: both
are characterized by an increased risk of WT and abnormal genito-
urinary development [4–6]. Somatic mutations of WT1 are seen in
10% to 20% of sporadic WT [7–9]. Frequently accompanying WT1
mutation is canonical Wnt activation, most commonly due to activat-
ing mutation of β-catenin (CTNNB1) [10,11]. Inactivating mutations
of WTX, a protein that contributes to β-catenin degradation, may also
occur in 15% to 20% of patients with WT, regardless of their WT1
mutation status [12–15]. While canonical Wnt- activating mutations
likely occur subsequent to WT1 mutation [16,17], whether or not
Wnt activation is required for tumor development afterWT1mutation
is not clear. Nor is the role of Wnt activation in WT that lack WT1
mutation known.
The WT2 chromosomal region came to scientific attention with
the observations of 11p15 loss of heterozygosity (LOH) or loss of im-
printing (LOI) in a large proportion of sporadic WT [18], and 11p15
uniparental disomy (UPD) or duplication in patients with Beckwith-
Wiedemann syndrome (BWS), which carries an increased risk of WT
and developmental abnormalities including organ and limb over-
growth [19–22]. 11p15 methylation abnormalities resulting in WT
are accompanied by aberrant methylation at imprint control region 1
(ICR1), resulting in biallelic expression of IGF2, a gene normally ex-
pressed only from the paternally inherited allele [21,23]. Although
11p15 clearly plays a critical role in the pathogenesis of WT, the obser-
vation of 11p15 LOH in normal tissue from someWT patients [24] and
the lack of tumors arising in mutant mice with ICR1 LOI [25] imply that
biallelic expression of IGF2 alone is insufficient for tumor development.
Other loci implicated in WT infrequently are the familial predis-
position loci FWT1 at 17q12-q21 and FWT2 at 19q13.4 [26,27].
The documented association between relapse and LOH for 1p and
16q [28] is being used to stratify patients within the current Children’s
Oncology Group therapeutic protocols. The critical genes within these
regions are not known.
In summary, despite the wealth of knowledge that the investigation
of WT has provided, much remains unknown and further progress
is made difficult by the genetic, histologic, and clinical heterogeneity
that characterizes WT. The goal of this study was to investigate pat-
terns of global gene expression and known genetic and epigenetic
changes in a large number of prospectively identified WTs to identify
and characterize distinctive subsets that may merit therapeutic stratifi-
cation or respond to specific therapies. In addition, the recent availability
of large data sets of gene expression patterns identified in microdissected
samples of different embryologic stages and in different cell types during
normal renal development [29,30] offers a unique opportunity to place
each of these WT subsets within their developmental context. We have
accomplished this, and here we provide a revised ontogenic model for
the development of WT.
Materials and Methods
Clinical Samples
Samples were taken from a case-cohort sampling previously de-
scribed [31]. Briefly, all patients with Favorable Histology Wilms
Tumor (FHWT) registered on the National Wilms Tumor Study 5
for whom pretreatment tumor tissues were available were identified.
From the resulting 1451 patients, all those known to have relapsed
and a random sample including approximately 30% of the remaining
were identified. The resulting 600 patients were randomly divided
into two groups of 300 patients each. The use of case-cohort sampl-
ing allows for the resource-efficient investigation of clinical outcome
in a tumor characterized by a low relapse rate. Institutional review
board approval and informed consent were obtained for all tumor
specimens. Frozen sections of each sample confirmed more than 80%
viable cellular tumor. Pathologic features (diagnosis, local stage, his-
tologic pattern, skeletal muscle quantification, presence, and type
of nephrogenic rests) were recorded prospectively at the time of
central pathology review. Skeletal muscle quantification represents
the estimated proportion of the tumor volume containing cells with
cross striations.
Neoplasia Vol. 14, No. 8, 2012 Ontogeny of Wilms Tumor Gadd et al. 743
Gene Expression Analysis
Samples were hybridized to Affymetrix U133A arrays, scanned,
subjected to quality control standards, and normalized as previously
described [32]. Gene expression patterns were identified through un-
supervised analysis using average linkage clustering with CLUSTER
and displayed with TreeView (http://rana.lbl.gov/EisenSoftware.htm)
[33]. Gene Set Enrichment Analysis v.2.5 (GSEA) was used to identify
those gene lists that best define the different tumor subsets. GSEA ranks
the expression of each gene based on its correlation with one of two
phenotypes being compared. It then determines the presence and rank-
ing of each gene within available independent gene lists queried. From
this ranking, it calculates an enrichment score that reflects the degree to
which genes in the independent gene list are overrepresented. The nor-
malized enrichment score (NES) takes into account the number of
genes within the independent gene set. Leading-edge genes are those
that account for the gene set’s enrichment signal.
Loss of Heterozygosity for 1p, 16q
Polymerase chain reaction (PCR) microsatellite analysis was per-
formed prospectively during National Wilms Tumor Study 5 as pre-
viously described in detail [28].
Methylation Analysis at 11p15 ICR1 and ICR2
Methylation of the paternally methylated ICR1 (controlling H19
and IGF2 expression) and the maternally methylated ICR2 (KvDMR1,
whose methylation is independent of ICR1) was determined using spe-
cific restriction sites recognized by methylation-sensitive enzymes as
previously described [34]. Retention of imprinting (ROI) was defined
as 30% to 70%methylation of both ICR1 and ICR2, LOI was defined
as 80% to 100%methylation of ICR1 and 30% to 70%methylation of
ICR2, and LOH was defined as 80% to 100% methylation of ICR1
and 0% to 20% methylation of ICR2. Tumors with values outside
these ranges were not classified.
11p15 Copy Number Analysis
Samples with 11p15 LOH were analyzed for 11p15 copy number
using multiplex ligation-dependent probe amplification (MLPA) to
assess for UPD (two identical copies of 11p15) using four probe sets
to loci on 11p15, as previously described [34].
Mutation Analysis for WT1, CTNNB1, and WTX
Tumor DNAs were assessed for WT1 point mutations by analysis
of PCR products from all 10 exons and for partial or complete dele-
tion of WT1 by quantitative real-time PCR analysis using amplicons
for the promoter/exon 1, exon 2/3, exon 4, exon 5, exon 6, exon 7,
exon 8/9, and exon 10 of WT1, as previously described [14,34,35].
Tumor DNAs were analyzed for point mutations in CTNNB1 (exons 3,
7, and 8), as previously described [10,14]. To detect WTX mutations,
the entire coding region was amplified as a single PCR product and
sequenced. Quantitative PCR was performed to detect deletions, as
previously described [14].
Results
Identification of Subsets of WT by Gene Expression Patterns
We first analyzed the global gene expression pattern of the 224 sam-
ples from the first group of 300 patients that passed quality control
parameters. Unsupervised hierarchical clustering using the top 2000,
4000, and 10,000 most variable genes demonstrated two subsets
(S1 and S2) that were stable in each analysis, identifying the same
samples within each subset (Figure 1A, blue and red bars). S1 and S2
tumors were then removed, the most highly variable genes were re-
identified from the remaining tumors, and hierarchical clustering was
again performed. This did not reveal new subsets with consistent
expression patterns.
A key gene differentially expressed in S2 tumors isWT1 (Figure 1A).
To better assess the role of WT1 in the overall expression pattern,
54 unique genes were identified due to their Pearson Correlation
Coefficient (PCC) scores of less than −0.6 or greater than 0.6 for both
available WT1 probe sets compared with all probe sets on the array.
Hierarchical analysis using these 54 genes again identifies S1 and S2
(Figure 1B, blue and red bars), as well as an additional subset, S3 (green
bar in Figure 1B). Lastly, two small groups of tumors flank the S2
tumors and are grouped together as S4 (Figure 1B, purple bars). There
is no evidence of clustering of the S3 and S4 tumors within the original
unsupervised analysis (Figure 1A). Tumors outside of S1 to S4 (the
majority of tumors) are classified as S5. The top 100 genes differentially
expressed in each of S1, S2, S3, and S4 compared with S5 as deter-
mined by GSEA are provided in Table W1. The gene expression data
are deposited inNational Center for Biotechnology Information’s Gene
Expression Omnibus, accessible at GEO Series accession no. GSE31403
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31403).
Clinical and Pathologic Features of FHWT Subsets
The features of WT within S1 to S4 are listed in Table 1, and
these results are compared with the remaining S5 tumors in Table 2
and are summarized below:
. Subset 1 tumors (n = 11) occur in infants and all have a distinctive
epithelial tubular differentiated histologic pattern throughout. All
lack both nephrogenic rests and skeletal muscle differentiation,
and none relapsed.
. Subset 2 tumors (n = 23) present at an early median age, have a mixed
(triphasic) histology and commonly arise within intralobar nephrogenic
rests (ILNRs). Of 22 evaluable S2 tumors, 9, 12, and 1 display mus-
cle differentiation comprising 5% or less, 10% to 25%, and 80%
of the tumor volume, respectively. Two relapses occurred, and two
additional patients developed contralateral tumors after therapy.
. Subset 3 tumors (n = 21) are pathologically similar to S2, with
less skeletal muscle differentiation. Of 21 evaluable tumors, 13, 4,
and 4 showed absent, 5% or less, and 10% to 25% skeletal muscle,
respectively. Seven relapses occurred.
. Subset 4 tumors (n = 11) are also pathologically similar to S2:
skeletal muscle differentiation was identified in 6 of 10 evaluable
S4 tumors, with 3, 2, and 1 showing 5% or less, 10%, and 40%
skeletal muscle, respectively. Six patients relapsed.
. Subset 5 tumors (n = 158): 70 triphasic (mixed), 76 blastemal
predominant, 9 epithelial predominant, and 3 stromal predom-
inant. Skeletal muscle is present in 27 (17%) of 156 evaluable
tumors (24/27 with <5%, 2 with 5%-15%). Of 154 evaluable
tumors, 38 (25%) contain perilobar nephrogenic rests (PLNR)
and 5 of 38 also contain ILNRs. ILNRs alone are identified in 23
(15%) of 154 tumors. Five of the 224 patients in this study had
bilateral WT at diagnosis, and all belong to S5. Fifty S5 patients
relapsed. It should be noted that while the relapse rates in these five
subsets show clear differences, they do not achieve statistical signifi-
cance; the small sample size may contribute to this.
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Figure 1. Hierarchical analysis of 224 FHWT: (A) Unsupervised hierarchical analysis using the 4000 probe sets with the highest coef-
ficient of variation. Two subsets are designated by the blue (S1) and red bars (S2). Also shown are the tumors identified in B in green (S3)
and purple (S4). Tumors that relapsed are designated in red at the top of the dendrogram. Expression of genes, clustered on the y axis, is
shown with levels ranging from high (red) to low (green). The expressions of the two WT1 probe sets are illustrated separately at the
bottom. Four tumors outside S1 that show solely epithelial tubular differentiation are marked with a red asterisk. See Table W1 for the
top 100 genes differentially expressed in S1 to S4 compared with S5. (B) Hierarchical analysis using the 54 genes with a Pearson cor-
relation coefficient greater than 0.60 or less than −0.60 for both available WT1 alleles. S1 and S2 are readily identified (blue and red
bars). Two additional subsets are now apparent, indicated by green (S3) and purple bars (S4). Genes associated with muscle differen-
tiation are marked. (C) Hierarchical analysis of Wnt targets with a coefficient of variation greater than 0.06. S1 (blue) and S2 (red) clus-
tered tightly together. Tumors in S3 (green) and S4 (purple) did not show evidence of strong Wnt activation and did not cluster.
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Table 1. Features of Tumors in Subsets.
Relapse Stage Histology (Weight) Age (months) Rests 11p15 Status 1p LOH 16q LOH Mutations
WT CTNNB1 WTX
Subset 1
WT00-082 No I Epithelial (390 g) 8 None ROI NO NO No No No
WT00-269 No I Epithelial (789 g) 10 None ROI NO NO No No No
WT00-177 No I Epithelial (333 g) 13 None ROI NO NO No No No
WT00-175 No I Epithelial (580 g) 14 None ROI NO NO No No No
WT00-054 No I Epithelial (207 g) 17 None ROI NO NO No No No
WT00-002 No I Epithelial (31 g) 18 None ROI NA NA No No No
WT00-173 No I Epithelial (86 g) 39 None ROI NO NO No No No
WT00-167 No II Epithelial (393 g) 91 None LOI NO NO No No No
WT00-153 No I Epithelial (485 g) 15 None ROI NO NO No No No
WT00-086 No I Epithelial (230 g) 6 None ROI NO NO No No No
WT00-185 No I Epithelial (315 g) 7 NE ROI NO NO No No No
Subset 2
WT00-196 No I Mixed 3 ILNR ROI NO NO No No No
WT00-270 No I Mixed 14 ILNR LOH NO NO No No No
WT00-171 No II Mixed 43 None LOH LOH NO No No No
WT00-237 No III Mixed 11 ILNR LOH NO NO No No Yes (XX)
WT00-216 No II Mixed 20 ILNR ROI NO NO No Exon 8 No
WT00-264 No I Mixed 41 None LOI NO NO No Exon 8 No
WT00-166 No I Mixed 37 None LOH NO NO No Exon 8 Yes (XX)
WT00-128 No I Mixed 57 ILNR LOH NO NO No Exon 7 Yes (XY)
WT00-074 No II Mixed 7 ILNR LOH NA NA No Exon 3 No
WT00-290 Yes II Mixed 27 ILNR ROI NO NO No Exon 3 No
WT00-027 No III Stromal 5 ILNR LOH NO NO Yes Exon 3 No
WT00-232 No I Mixed 12 ILNR ROI NO NO Yes Exon 3 No
WT00-152 No II Mixed 70 ILNR ROI NO NO Yes Exon 3 No
WT00-254 No III Mixed 35 None ROI NO NO Yes Exon 3 No
WT00-288 No II Mixed 8 ILNR LOH NO NO Yes Exon 3 Yes* (XY)
WT00-156 No II Mixed 9 ILNR LOH NO NO Yes Exon 3 No
WT00-061 Yes II Stromal 9 ILNR LOH NO NO Yes Exon 3 No
WT00-072 No II Mixed 13 ILNR LOH ND ND Yes Exon 3 No
WT00-113 No III Stromal 9 ILNR LOH NO NO Yes Exon 3 No
WT00-244 No III Mixed 12 ILNR ROI NO NO Yes Exon 3 No
WT00-064 No III Mixed 13 None LOH NO NO Yes Exon 8 Yes (XY)
WT00-193 No II Mixed 111 ILNR LOH ND ND Yes Exon 7 Yes (XY)
WT00-112 No III Blastemal 39 None ND NO LOH ND ND ND
Subset 3
WT00-110 No II Mixed 57 None LOI NO NO No No No
WT00-285 No III Mixed 57 ILNR LOH NO NO No No No
WT00-142 No III Mixed 55 None ROI NO NO No No No
WT00-127 No I Mixed 17 ILNR LOI NO NO No No No
WT00-135 Yes II Mixed 5 ILNR ROI NO NO No No No
WT00-220 No II Mixed 36 ILNR LOH LOH LOH No No No
WT00-277 Yes III Mixed 120 NA ROI NO NO No No No
WT00-209 No III Mixed 35 None ROI NO NO No No Yes (p.XX)
WT00-098 No II Mixed 41 ILNR LOI NO NO No No Yes (p.XX)
WT00-291 Yes III Mixed 28 ILNR ROI NO NO No Exon 3 No
WT00-205 No I Mixed 44 ILNR ROI NO NO Yes Exon 3 Yes (p,XY)
WT00-214 No II Mixed 0.2 ILNR ROI NO NO Yes Exon 3 No
WT00-038 No I Mixed 21 ILNR ROI NO NO Yes Exon 3 No
WT00-145 Yes III Mixed 10 ILNR ROI NO NO Yes Exon 3 No†
WT00-106 Yes I Mixed 10 ILNR LOH NO NO Yes Exon 3 No
WT00-023 No I Mixed 11 ILNR LOH LOH LOH Yes Exon 3 No
WT00-297 No II/IV Mixed 39 ILNR LOH NO NO Yes Exon 8 No
WT00-192 No III Blastemal 36 ILNR ROI NO NO Yes No Yes (XY)
WT00-121 Yes III/IV Blastemal 87 ILNR LOH NO NO Yes No No†
WT00-052 Yes II Blastemal 53 ILNR LOI NO NO Yes No Yes (XX)
WT00-122 No III Mixed 58 None LOH NO NO Yes(p) No No
Subset 4
WT00-026 Yes I Mixed 8 ILNR LOH NO NO Yes No No
WT00-204 Yes IV Mixed 73 None ROI NO NO No Exon 8 Yes (XX)
WT00-076 No III Mixed 72 None LOI NO NO No No Yes (XY)
WT00-172 No II Mixed 38 None LOH NO NO No No No
WT00-206 Yes III Mixed 65 ILNR LOH NO LOH No Exon 8 No†
WT00-276 No I Mixed 20 ILNR LOH NO NO No Exon 3 No
WT00-018 No II Mixed 56 Incon LOH ND ND No Exon 3 No
WT00-021 No II Mixed 17 None LOI NO NI No Exon 8 No
WT00-050 Yes I Mixed 15 None ROI NO NO No No No
WT00-190 Yes II Mixed 73 None ND NO NO ND ND ND
WT00-168 Yes IV Blastemal 37 NE LOI NO LOH No No No
ND indicates not done; NE, not evaluable; NI, not informative; p, partial.
*Missense mutation, unknown significance.
†Missense mutation, known single nucleotide polymorphism.
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Characterizing Subsets of FHWT Based on Gene Expression
GSEA was used to characterize the gene expression patterns in the
different subsets using the gene lists provided in Table 3. S1 to S4
tumors were individually compared with S5 tumors; S3 and S4
tumors were also compared with S2 tumors. Those gene lists with
a false discovery rate (FDR) of 20% or less and nominal P ≤ .05
are provided in Table W2. These are grouped into categories accord-
ing to their common leading edge genes, and these categories are pro-
vided in Table 4. The results of the above analyses are summarized
below, beginning with the largest group, S5. The expression patterns
of illustrative genes (designated with an asterisk [*] in the text) are
shown in Figure 2.
S5 tumors, the comparison group for this study, show a pattern
of expression previously reported by others in WT [32,36,37]. This
includes expression of SIX1, PAX2, EYA1, SALL2, HOXA11*,
HOXA9, MEOX1, MEIS2*, PRAME, NNAT, CRABP2, FZD7,
COL2A1, GPR64, WASF, HMGA2*, UCHL1, and CCND2, most
of which are known to be expressed within the early metanephric mes-
enchyme (MM). S5 shows gene expression heterogeneity (Figure 1A);
however, no expression patterns are sufficiently stable to enable identi-
fication or validation. When analyzed alone, S5 tumors did not cluster
based on 11p15 methylation, 1p or 16q LOH, nephrogenic rest, pres-
ence of muscle differentiation, histologic pattern, or relapse status.
S1 tumors show significantly decreased expression levels of the
above renal developmental genes expressed in S5, and negative enrich-
ment of genes expressed in WTs compared with fetal kidney (LI) and
genes expressed in the preinduction MM (Brunskill A), illustrated by
HMGA2*, MEIS2*, and HOXA11*. Instead, genes expressed sub-
sequent to mesenchymal-to-epithelial transition (Brunskill groups D
and L) are enriched in S1. Several metabolic processes are signifi-
cantly enriched in S1 tumors, largely driven by AKR1C3*, a gene
expressed in the maturing epithelial component of the developing
kidney [29,38]. Similarly, the Notch signaling pathway, key to renal
epithelial differentiation, is significantly enriched in S1 tumors. To
evaluate whether S1 gene expression was driven solely by epithelial
differentiation, four non-S1 tumors with the same histologic pattern
were identified from all 224 tumors. They demonstrated different
gene expression patterns (red asterisks in Figure 1A), were older at
diagnosis (56, 58, 71, and 85 months), and presented at higher stages
(one stage I, one stage II, and two stage III tumors) when compared
with S1. Two were associated with nephrogenic rests, two of four
relapsed, and all demonstrated LOI at 11p15. These features all differ
from those of S1 and indicate that the S1 expression profile is not
simply a function of epithelial differentiation.
Subset 2 tumors show enrichment of a very large number of GO
Biologic Processes gene lists, many of which have in common early
muscle development genes, includingMYH3* (myosin), TTN* (titin),
and ACTA1* (actin), to name a few. Notably, the degree of expression
of these muscle-related genes far exceeded the histologic evidence of
muscle differentiation in most tumors, which was often quite focal.
A wide variety of processes involved in the morphogenesis of other cell
types is also enriched. Noteworthy is the increased expression of tran-
scription factors TWIST1* and PITX2*. Both cell proliferation and
programmed cell death gene lists are enriched, largely driven by
TBX3*,MYC, LGALS1, PLAGL1, FABP7, and IGF1. Signal transduc-
tion was likewise enriched, particularly Ras signaling, driven by IGF1.
Of the curated canonical pathways, NFAT and TGFB signaling were
enriched in S2. This supports the premise previously proposed that
WT1 loss may lead to TGFB activation, resulting in NFAT induction,Ta
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which in turn mediates the switch of TGFB from growth inhibitor to
growth promoter [39,40]. The genes differentially expressed between
WTs with and withoutWT1mutation (TYCKO) are concordantly dif-
ferentially expressed in S2 tumors, including striking up-regulation of
WIF1* and down-regulation of HAS2 and KLK6*. Genes differentially
expressed in WT with CTNNB1 mutation (ZIRN) are likewise en-
riched. Lastly, S2 tumors show significant enrichment of genes normally
expressed before induction (LIN intermediate mesoderm, Brunskill
group A) and in the renal interstitium (Brunskill groups M, N, and O).
Taken together, S2 tumors show evidence of loss of WT1 expression,
Wnt activation, and divergent mesenchymal differentiation, all occur-
ring quite early in renal development.
Subset 3 tumors show an overall expression pattern similar to that
of S5 (Figure 1A). This is supported by the absence of enrichment of
C5 gene ontology biologic processes, C2-curated canonical pathway
gene lists, and renal development gene lists analyzed when comparing
S3 to S5 (Table 4). However, there are significant differences between
S3 and S5. More than 95% of the top genes differentially expressed
between S3 and S5 tumors are also coordinately differentially expressed
when comparing S2 to S5 (Table W1). Similarly, the gene lists differ-
entially expressed in both WT1 (TYCKO) and CTNNB1 (ZIRN)
mutant WT and the Stanford Wnt targets showed the same pattern
in S3 and S2 tumors. These observations are consistent with the fact
that S3 tumors were identified based on genes coordinately expressed
Table 3. Gene Lists Analyzed by Gene Set Enrichment Analysis.
Gene Lists Reference
All lists in GSEA v 2.5 from Gene Ontology Biologic Processes with >50 genes (C5): 225 lists www.broadinstitute.org/gsea
All lists in GSEA v 2.5 from curated canonical pathways with >50 genes (C2): 88 lists www.broadinstitute.org/gsea
List comparing WT to fetal kidney (LI) [36]
Lists comparing WT with and without WT1 mutation (TYCKO) [42]
Lists comparing WT with and without CTNNB1 mutation (ZIRN) [66]
STANFORD Wnt signaling www.stanford.edu/~rnusse/wntwindow.html
15 lists characterizing different stages and cell types within the developing kidney (Brunskill A-0) [29]
List characterizing the intermediate mesoderm (LIN) [30]
Table 4. GSEA of S1 to S4 Compared with S5.
Subset 1 Median NES:
S1 vs S5
Median NOM P :
S1 vs S5
Median FDR:
S1 vs S5
(A) GO biologic processes
Mitosis/cell cycle −1.65 .03 0.07
DNA replication −1.56 .05 0.08
Metabolic processes 1.67 .004 0.08
(B) Curated and published lists
LI_FETAL_VS_WT_KIDNEY_DN −1.64 .02 0.02
LI_FETAL_VS_WT_KIDNEY_UP 1.55 .03 0.08
NOTCH_SIGNALING_PATHWAY 1.78 <.001 <0.01
(C) Renal developmental lists
Brunskill A: Early MM −1.41 .03 0.17
Brunskill D: Renal vesical, S body 1.56 .03 0.09
Brunskill L: Epithelial differentiation 1.5 .05 0.07
S2, S3, S4 Median NES:
S2 vs S5
Median NOM P:
S2 vs S5
Median FDR:
S2 vs S5
Median NES:
S3 vs S5
Median NES:
S4 vs S5
Median NES:
S3 vs S2
Median NES:
S4 vs S2
(A) GO biologic processes
Muscle development 1.75 <.001 0.01 NS 1.62 −1.74 NS
Morphogenesis and development 1.71 <.008 0.02 NS 1.71 −1.67 NS
Regulation of catalytic activity 1.61 <.001 0.05 NS 1.43 −1.54 NS
Regulation of transferase/kinase 1.46 .001 0.02 NS NS NS NS
Cell cycle 1.49 .012 0.12 NS NS −1.47 NS
Signal transduction 1.77 .002 0.01 NS 1.71 −1.65 NS
Metabolic process 1.59 .006 0.06 NS NS NS NS
(B) Curated and published lists
TYCKO_UP_IN_WT1_WILDTYPE_WT −1.68 <.001 0.01 −1.71 −1.55 1.50 1.51
TYCKO_UP_IN_WT1_MUT_WT 1.40 .002 0.13 1.5 1.49 −1.41 −1.54
ZIRN_UP_IN_CTNNB1_MUT_WT 1.60 <.001 0.03 1.58 1.74 −1.49 NS
ZIRN_DOWN_IN_CTNNB1_MUT_WT −1.66 .004 0.01 −1.79 NS NS NS
STANFORD_WNT_GENES_UP 1.86 <.001 0.01 1.92 1.76 −1.67 NS
NFATPATHWAY 1.80 <.001 0.06 NS 1.70 −1.82 NS
TGF_BETA_SIGNALING_PATHWAY 1.51 .02 0.18 NS NS NS NS
(C) Renal developmental gene lists
LIN intermediate mesoderm 1.6 .004 0.004 NS 1.66 −1.64 NS
Brunskill A: Early MM 1.58 .003 0.03 NS 1.60 −1.57 NS
Brunskill M, N, O: interstitium 1.66 .003 0.03 NS 1.59 −1.62 NS
Categories of gene lists with an FDR of 20% or less and nominal P ≤ .05.
Individual gene lists and their leading-edge genes are provided in Table W2.
FDR indicates false discovery rate (median of all gene lists in category); NES, nominal enrichment Score (median of all gene lists in category); NOM, nominal P value (median of all gene lists in category);
NS, not significant (P > .05 or FDR > 0.20).
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Figure 2. Patterns of gene expression within the different subsets of FHWT: The log expression levels (low to high) of selected genes
are plotted on the y axis. The x axis reflects an arbitrary tumor number, grouping the different tumor types starting with S1 in blue,
followed S2 in red, S3 in green, S4 in purple, and the remaining tumors (S5) in turquoise.
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with WT1 and with the observed down-regulation of WT1 in S3
tumors (Figure 1B). Direct comparison of S3 with S2 tumors reveals
negative enrichment of most of the same GO categories, canonical
pathways, and renal developmental categories previously identified
when comparing S2 with S5. In particular, this includes a low expres-
sion of genes involved with skeletal muscle differentiation in S3
(Figure 1B), as well as NFAT, TGFB, and Ras signaling. Lastly, whereas
S3 tumors show greater canonical Wnt activation than S5 tumors do
(NES = 1.9, nominal P < .001, FDR = 1%), there is negative enrich-
ment of Stanford Wnt targets in S3 compared with S2 (NES = −1.67,
nominal P < .001, FDR = 0.03). In summary, while similarities be-
tween S2 and S3 point toward low WT1 expression, the differences
lie in decreased canonical Wnt activation and decreased divergent
mesenchymal differentiation in S3 tumors and disruption of S3 tumors
later in renal development than that of S2 tumors.
S4 tumors show an overall gene expression pattern quite similar to
that of S2 (Figure 1B), and none of the biologic processes, canonical
pathways, or renal developmental gene lists are significantly enriched
in the comparison of S2 with S4. The one list that differed included
genes differentially expressed in tumors with WT1 mutation, which
were downregulated in S4 (TYCKO; Table 4). Comparing S4 to S5,
more than 95% of the top differentially expressed genes are also con-
cordantly differentially expressed in S2, and S4 shows significant
enrichment of many of the same gene lists enriched in S2 compared
with S5, including one of twoWnt signaling gene lists (Table 4). Wnt
activation was not evident in Figure 1. In summary, the S4 gene
expression pattern is quite similar to S2, supporting an origin very
early in renal development, although with somewhat less evidence
of Wnt activation and WT1 loss.
WT1, CTNNB1, and WTX Mutation Analysis
S1 to S5 show differences in expression of genes associated with
WT1 loss and Wnt activation. Therefore, mutation analysis was
performed for WT1, CTNNB1, and WTX within S1 to S4 tumors
(Table 1). S1 lacks mutations in any of these genes. Whereas ∼50%
of S2 and S3 tumors contain abnormalities of WT1, only 10% of
S4 tumors containWT1 genetic events, corresponding to the different
enrichment pattern seen in the TYCKO gene lists. The documenta-
tion of WT1 mutation in only ∼50% of S2 to S4 tumors that show
loss of WT1 expression suggests that other mechanisms for WT1
mRNA loss exist. S2 to S4 show variable evidence of CTNNB1 exon 3
mutations (those known to stabilize β-catenin); the highest frequency is
seen in S2, and the lowest, in S4. This parallels the Wnt target expres-
sion patterns in these subsets.WTXmutation is identified in 13 (24%)
of 53 S2 to S4 tumors and did not vary significantly across these
subsets. As previously reported, WTX mutation was associated with
CTNNB1 exon 7, 8 mutations [41]. Comparison of gene expression
patterns did not show detectable differences when comparing those
S2 to S4 tumors with and without WTX mutations (data not shown).
Canonical Wnt Activation
To further investigate Wnt signaling and to determine whether
mutation analysis was merited for S5, hierarchical analysis was per-
formed using the Stanford Wnt targets (Figure 1C ). S1 tumors cluster
together because of increased expression of targets such as LEF1 and
FZD2 and decreased expression of CCND1 and JAG1. S2 tumors
show strong expression of a large number of canonical Wnt targets
including those involved in muscle differentiation (PITX*, ISLR)
and extracellular inhibitors of Wnt signaling (WIF1*, DKK1, and
DKK2*). Overexpression of these inhibitors has been attributed to
cellular resistance to feedback inhibition in the setting of constitutive
Wnt activation [42]. Three S2 tumors lacking CTNNB1 orWTXmu-
tations show strong evidence ofWnt activation, suggesting the presence
of other mechanisms for canonical Wnt activation, as reviewed previ-
ously [43]. S3 and S4 tumors show no clear evidence of canonical Wnt
activation and relative decrease in the expression of Wnt inhibitors
WIF1*, DKK1, and DKK2*, suggesting insufficient constitutive Wnt
activation to trigger this feedback inhibition. S5 lacks overt patterns
of differential expression of Wnt targets in these analyses.
11p15 Analysis
Methylation analysis of ICR1 and ICR2 was performed on 205 of
224 tumors with sufficient remaining frozen tissue (Tables 1 and 2).
This confirms the presence of tumors with the biallelic paternal but
not maternal methylation patterns (Figure 3A). The considerable ma-
jority of S1 tumors retain the normal methylation pattern. LOI is rare
in S2 and increases in both S3 and S4. In contrast, LOH is high in S2
and decreases in S3. All of the S2 to S4 tumors with 11p15 LOH are
disomic by copy number analysis, consistent with UPD. Lastly, the
majority of S5 tumors show biallelic methylation of ICR1 resulting
from either 11p15 LOH (37.2%) or LOI (43.8%). This does not result
in a significant differential expression of IGF2 because IGF2* is highly
expressed in virtually all tumors outside S1.
Because 11p15 LOH is usually copy neutral in WT due to UPD,
the gene expression consequences of 11p15 LOH and 11p15 LOI are
presumed to be largely the same. This is supported by a comparison of
S5 tumors with 11p15 LOH versus those with LOI. Significant dif-
ferential expression of only a few genes was identified, one of which is
CDKN1C (fold change [FC] = 0.5, P = 2 × 10−6), whose expression is
controlled by ICR2 (with biallelic methylation in LOH). Other genes
controlled by ICR2 (PHLDA2, SLC22A1L, KCNQ1DN, KCNQ1,
andMTR1) were not significantly differentially expressed, and no other
genes of biologic relevance were identified.
1p and 16q LOH
The considerable majority of tumors showing LOH at these two
regions reside in S5. S5 tumors did not cluster according to 1p and
16q LOH status.
Validation of Subsets in an Independent Tumor Set
Gene expression and 11p15 methylation analysis were performed on
an independent set of 100 tumors from the second group of 300 sam-
ples. Hierarchical analysis using the top genes provided in Table W1
demonstrates three subsets of tumors, classified as SA, SB, and SC
(Figure 3B). The clinical, pathologic, and 11p15 methylation features
of these three subsets, and of the remaining 80 tumors (classified as
SD), are provided in Table 2. Subsets A, B, C, and D show the same
gene expression and 11p15 methylation patterns, and the same clinico-
pathologic features as S1, S2, S3, and S5, respectively. An exception is
the difference in median age noted between S2 and S3, which was not
observed in SB and SC. This is likely a reflection of the broad age ranges
seen in S2 and S3 combined with the smaller number of tumors in the
validation set (Table 1). Because the top gene lists for S2 and S4 in
Table W1 are very similar, it is possible that the above analysis using
these lists would not adequately differentiated S2 and S4. To better
evaluate for the presence of S4-like tumors within the validation set,
we clustered the initial 224 samples combined with the 100 valida-
tion samples using the 54 genes associated with WT1 expression (the
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analysis that detected S4 tumors originally). This resulted in clustering
of all SA, SB, and SC tumors with S1, S2, and S3 tumors, respectively
(data not shown). None of the validation tumors clustered with S4.
Discussion
Wilms tumors (WT), like most pediatric embryonal neoplasms, have
been postulated to arise from cells undergoing differentiation during
organogenesis. WT commonly display a triphasic histology remark-
ably similar to cells at different stages of differentiation of the normal
MM: blastemal cells similar to early-stage MM, stromal cells, and
epithelialized cells arranged in duct-like structures. This histology and
the known clonality of these tumors imply that a cell from which a
tumor arises is not only very plastic in its differentiation capacity but
that progeny cells can exhibit very different cell fates. The current study
has been able to delineate, based on gene expression analysis, distinct
subsets of tumors with different molecular, clinical, and pathologic
features. These subsets exhibit different mutation patterns as well as
different gene expression profiles characteristic of different stages of
differentiation. This suggests that tumor subset identity is a result of
the interplay of the type of initiating event, the stage of differentiation
of the tumor cell of origin, and also its cellular context.
The genitourinary system develops from the intermediate meso-
derm, from which the gonads, the mesonephros, and the metanephros
(including both the ureteric bud and the primitive MM) develop. Re-
ciprocal interactions between the ureteric bud and the MM are respon-
sible for induction within the MM, which occurs through canonical
Wnt signaling. After initiation of induction, mesenchymal-to-epithelial
transition begins, enabling the formation of the nephron [44]. Epithe-
lial segmentation, mediated largely by Notch signaling, leads to the
development of the glomerular pole proximally and the tubular pole
Figure 3. 11p15methylation and subset validation. (A) ICR1 and ICR2methylation: Three patterns of methylation were identified: 11p15 LOH
(80%-100%methylation of ICR1 and 0%-20%methylation of ICR2), 11p15 LOI (80%-100%methylation of ICR1 and 30%-70%methylation
of ICR2), and 11p15 ROI (30%-70% methylation of both ICR1 and ICR2). Tumors with values outside these ranges were not classified.
(B) Validation with an independent set of 100 FHWT: Hierarchical analysis was performed using the top genes from Table W1. This demon-
strates three subsets of FHWT with the same clinical and pathologic features of S1, S2, and S3 of the training set.
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distally. As has been reported previously for WT, most WTs in our study
(those of S5) express genes that characterize the MM [32,36,37]. Be-
cause the current study analyzes a very large panel of relapse enriched
but otherwise unselected WTs for which substantial clinical and molec-
ular information is available, we were able to identify additional subsets
of WT with different clinical and pathologic features that show evi-
dence of disruption at different times during normal development.
S1 tumors show gene expression patterns similar to the late postinduc-
tion epithelial phase of renal development. The gene expression pat-
terns of S2 and S4 show similarities to the intermediate mesoderm or
very early MM. S3 and S5, while displaying unique gene expression
patterns, do share a profile similar to the MM. To arrive at the on-
togeny of WT, these developmental profiles need to be analyzed in
conjunction with the genetic events known to be pathogenetically im-
portant in WT.
WT1 in Renal Development and in WT
As demonstrated by the Wt1−/− mouse,WT1 expression is low but
essential for cell survival within the intermediate mesoderm [2,45].
This is followed by increased WT1 expression in the MM. Somatic
ablation of Wt1 in mice soon after nephrogenesis commences results
in a block in the formation of epithelial structures [25], consistent with
its critical role in the mesenchymal-to-epithelial transition [46]. The
expression of WT1 within the different tumor subsets reflects the
changing role of WT1 during development as well as the phenotypic
effects after its loss, often through mutation. WT1 is highly expressed
in S5, in keeping with its expression within the MM, where WT1 is
normally highly expressed.WT1 is also highly expressed in S1, in keep-
ing with highWT1 expression normally seen within early epithelial ele-
ments. S2 to S4 tumors show low WT1 expression (often because of
mutation), which is frequently associated with stromal elements. This
is consistent with experimental data demonstrating that loss of WT1
disrupts the normal differentiation of epithelial nephronic elements
but has no salient effect on stromal development [25].
Canonical Wnt Activation in Renal Development and in WT
Within the MM, canonical Wnt activation is required for the
mesenchymal to epithelial transition to occur; however, subsequent
Wnt down-regulation is also required to allow the fully epithelial state
of the renal vesicle to develop [47–49]. S1 to S5 tumors show varia-
tion in canonical Wnt activation concordant with the timing of their
developmental arrest or secondary to genetic changes. No evidence of
Wnt activation using these analytic tools is identified in S5, in keeping
with their origin around the time of induction. Similarly, S1 tumors
show evidence of the canonical Wnt down-regulation required for full
epithelial differentiation. Strong constitutive canonical Wnt activa-
tion is identified in S2 tumors, with only weak Wnt activation in S3
and S4 tumors, correlating with the incidence of CTNNB1 exon 3
mutation in the subsets (55%, 33%, and 20%, respectively). Canonical
Wnt signaling is required for mesenchymal stem cell self-renewal and
several of the Wnt pathway genes overexpressed in S2 tumors are
mesenchymal stem cell markers, including MET and LGR5 [50,51].
Therefore, for cells of the intermediate mesoderm or early MM that
have lost WT1 (and are therefore unable to complete epithelial differ-
entiation as outlined above), constitutive Wnt activation would be
predicted to result in the continued blastemal and mesenchymal cell
proliferation and development of S2 tumors.WT1 loss somewhat later
in development (after the normal reduction of canonical Wnt activa-
tion) may be less sensitive toCTNNB1mutation and require a different
secondary genetic event to achieve abnormal proliferation sufficient to
result in tumor development, as discussed further below. It is important
to note that Wnt signaling is a remarkably complex and cell type– and
stage-dependent. Therefore, the above studies do not fully evaluate ca-
nonical or noncanonical Wnt signaling in any of the subsets described.
11p15 Alterations in Renal Development and WT
IGF2 expression is high in the undifferentiated MM. After induc-
tion, IGF2 is dramatically reduced in the epithelial cells but remains
high in the stromal cells [52]. Therefore, the patterns of expression of
IGF2 andWT1 during renal development are complementary, and dif-
ferences in S1 to 5 tumors would therefore be expected. S1 shows re-
tention of the normal methylation pattern at 11p15 and lower IGF2
expression, in keeping with postinduction epithelium. In contrast, S5
tumors show high IGF2 expression, consistent with the very high prev-
alence of biallelic methylation of ICR1 (81%). S2 to S4 tumors require
more careful consideration: 49% of S2 to S4 tumors show evidence of
copy neutral 11p15 LOH, known as UPD. UPD occurs when one
chromosome (or part thereof) is lost and the second copy is duplicated,
usually due to chromosome loss and reduplication or mitotic recom-
bination. In cells that sustain a WT1 mutation in one allele, UPD
for chromosome 11 represents a common mechanism for losing the
remaining normal WT1 allele. UPD (LOH) at 11p15 will also occur
in this situation as an epiphenomenon. Because WTs displaying LOH
invariably lose the maternally derived chromosome/chromosome seg-
ment [53], WT1 mutant tumors often therefore carry two copies of
all paternally imprinted genes. In contrast, the mechanisms that cause
11p15 LOI are confined to 11p15 and can be independent of 11p13
and the WT1 gene. S2 to S4 tumors show an increasing prevalence of
11p15 LOI (4.5%, 19%, and 30%, respectively). LOI was identified in
6 of 16 S2 to S4 tumors lacking CTNNB1 mutations, but in none of
the 21 S2 to S4 tumors with CTNNB1 exon 3 mutations. These ob-
servations suggest that 11p15-biallelic methylation (either LOH or
LOI) may be a second genetic event in the pathogenesis of at least some
S2 to S4 tumors and may functionally substitute for CTNNB1 muta-
tions with regard to malignant development. This provides support to a
previous study that carefully detailed the 11p15 copy number and
methylation analysis, WT1 mutation parameters, and the CTNNB1
status of 36 WT with WT1 alterations provided by Haruta et al.
[54]. Interestingly, a mouse model was recently reported that required
the introduction of both WT1 mutation and IGF2 overexpression to
produce murine WT [25].
A Revised Model for WT Ontogeny
Themost prevalent model forWT development is bifurcated. In one
arm, biallelic WT1 mutation results in the development of an ILNR
followed by additional genetic changes (e.g., Wnt-activating muta-
tions), resulting in WT development. In the second arm, genetic or
epigenetic changes result in biallelic 11p15 ICR1 methylation and de-
velopment of a PLNR, followed perhaps by additional genetic changes
leading to WT development. The data presented in our study confirms
these two groups but supports additional heterogeneity that requires
revision of this model, as described below (Figure 4).
Subset 1 tumors are characterized by 1) enrichment of genes
expressed in the renal epithelium after induction, 2) high WT1 ex-
pression, 3) decreased IGF2 expression, and 4) decreased expression
of Wnt targets. They lack WT1, CTNNB1, and WTX mutations,
retain heterozygosity for 1p, and 16q, and retain the normal imprint-
ing pattern at 11p15. We propose that S1 tumors arise in the late
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postinduction MM within a cell characterized by high expression of
WT1, low expression of IGF2, and repression of canonical Wnt signal-
ing. S1 tumors do not arise within nephrogenic rests, and the respon-
sible genetic event(s) has not been identified.
Subset 2 tumors show 1) enrichment of genes expressed in the
intermediate mesoderm and early MM, 2) loss ofWT1 expression often
due to WT1 mutation, 3) canonical Wnt activation accompanied by a
high CTNNB1–exon 3 mutation frequency, and 4) divergent mesen-
chymal differentiation, previously attributed to WT1 loss and/or
canonical Wnt activation [41,55–58]. In addition, 25% of tumors
showed WTX mutation, which has been associated with expansion of
early mesenchymal precursors within the developing kidney [59]. We
propose that S2 tumors arise within cells of the intermediate mesoderm
or early MM after inactivation of oneWT1 allele followed by loss of the
second WT1 allele, commonly through chromosomal mechanisms re-
sulting in UPD for 11p13. (Incidental UPD for 11p15 also occurs;
however, during this developmental window, biallelic expression of
IGF2 would not be expected to be as significant because the IGF2 levels
are already quite high.) Loss of WT1 perturbs normal nephron devel-
opment with preferential expansion of mesenchymal elements (which
do not requireWT1), resulting in an ILNR. Within the ILNR, an ad-
ditional genetic event (such as CTNNB1 or WTX mutation) results in
Wnt activation accompanied by continued proliferation of primitive
mesenchymal cells and increased diversion into alternate pathways,
including muscle differentiation. The mixed histology observed in S2
tumors supports an origin before the delineation of nephron- or
stroma-fated compartments occurs.
Subset 3 tumors show similarities with S2 tumors owing to their
common primary pathogenetic feature (low WT1 expression). How-
ever, they differ by their decreased evidence of canonical Wnt activation
and decreased divergent mesenchymal differentiation. In addition, S3
tumors lack enrichment of genes expressed in the intermediate meso-
derm and instead show the same expression of MM genes seen in S5
tumors. We therefore propose that S3 tumors show a similar sequence
of genetic events to S2, although these events occur in cells of the MM
later in development, at a time whenWT1 expression is increasing and
IGF2 expression is decreasing. In addition, the different timing is asso-
ciated with a different sensitivity to (or requirement for) Wnt-activating
mutations and therefore to differences in divergent mesenchymal dif-
ferentiation. Our study provides data supporting the hypothesis previ-
ously reported that 11p15 ICR1 biallelic methylation may represent an
alternative second event [54].
S4 tumors have a gene expression pattern similar to S2, although
they have a lower incidence of WT1, CTNNB1, and WTX muta-
tions (and corresponding expression patterns) and a high incidence
of biallelic methylation of ICR1 (80%) similar to S5. Nonetheless,
they are defined by their WT1-associated gene expression pattern.
These tumors may therefore have alternative genetic/epigenetic ab-
normalities up- or downstream to WT1. The small number of tu-
mors within this subset and our inability to validate this subset
suggests caution is needed with regard to S4. The intriguing clinical
and genetic differences, particularly the high relapse rate, support the
continued retention of this subset pending further knowledge.
S5 tumors display the gene expression pattern of the MM and a
high frequency of biallelic methylation of ICR1 at 11p15. This sup-
ports assertions that approximately 70% of WT arise, in part, due to
abnormal expression of normally imprinted 11p15 genes [21,23]. It
also corroborates an association between an older age at presentation,
histologic pattern, and 11p15 LOI in WT [60]. S5 is notable for
being the only subset in which PLNRs were observed, although
ILNRs were also seen and some tumors contained both. Patients
with BWS are known to develop both ILNRs and PLNRs [1]. This
suggests that factors such as the cell type or the timing of the initial
genetic event may determine the type of nephrogenic rest and the
heterogeneous WT histology that results. We propose that S5 tumors
arise within cells of the MM at a time when IGF2 expression is di-
minishing. Biallelic methylation of ICR1 during this developmental
window results in increased IGF2 expression and the development of
a nephrogenic rest. If biallelic methylation of ICR1 occurs before in-
duction, the persistent elevation of IGF2 causes preferential mesen-
chymal proliferation and prevents nephron development, resulting in
an ILNR. If manifested after induction within early nephronic cells,
persistent IGF2 elevation prevents terminal epithelial differentiation,
resulting in the development of a PLNR. This is supported by the
Figure 4. Revised model for WT ontogeny. See text for description.
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presence of high WT1 and IGF2 expression in primitive epithelial
structures of WT, whereas IGF2 expression is low in normal termi-
nally differentiated epithelial renal elements [52]. Within the result-
ing nephrogenic rest (be it ILNR or PLNR), a second genetic event
likely occurs resulting in tumor development. The absence of tumor
development in a mutant mouse strain with biallelic Igf2 expression,
but no other genetic alteration, would suggest that a second event is
required [25], although the nature of this putative second event in S5
is still unknown.
An important question that remains is whether S5 is a unique en-
tity or simply a conglomeration of tumors that failed to cluster within
S1, S2, S3, or S4. Our study accumulates evidence supporting the
unity of S5, as outlined below:
. More than 80% of S5 tumors show somatic biallelic methylation
of ICR1, a constitutional abnormality seen in patients with BWS,
which is associated with WT development.
. The clinical and pathologic features of tumors arising in patients
with BWS (including precursor lesions) are the same as those iden-
tified in S5 tumors that are not associated with BWS.
. We could not identify other clusters within S5 based on gene
expression, even when S1 to S4 were removed.
. S5 tumors did not show subclusters based on any clinical or
pathologic parameter analyzed in this study.
. We have considerable experience observing the variation of gene
expression within pathogenetically homogeneous populations
of tumors, contrasted with the differences in expression be-
tween different tumor types, even when they are histologically
similar [31,32,61–63]. The S5 tumors show the range of vari-
ation that is expected within a group of tumors that share an
underlying pathogenesis.
In summary, while we cannot exclude the presence of biologically
distinctive subsets within the larger group of S5 tumors, in our opin-
ion, the prevailing evidence supports the hypothesis that S5 tumors
represent a single entity united by their underlying pathogenesis.
Significance
The categorization by gene expression analysis of prospectively
identified WTs resulted in the delineation of biologically unique sub-
sets with distinctive mutational spectra and clinical outcomes. Not
only does this provide insight into the pathogenesis of these subsets
and an explanation for their heterogeneity, but more importantly,
defining subsets driven by different genetic events may allow for both
subset-specific and targeted therapeutic strategies. Our data suggest
that therapies targeting the IGF receptor may be broadly applicable
to WT outside S1, whereas the use of therapies involving the Wnt,
TGFB, and NFAT pathways, when available, may have activity re-
stricted to particular subsets. The future therapy of infants with low-stage
disease will be particularly affected by subset-specific strategies for re-
ducing chemotherapy. Currently, patients younger than 24 months
with stage I FHWT weighing less than 550 g are defined as very low
risk WT (VLRWT) and are treated with surgery alone. S1 seems to be
responsible for approximately 30% of VLRWT who did not receive
adjuvant chemotherapy [34,60,64]. In the current study, S1 tumors
also occurred in patients older than 24 months, with nephrectomy
weights more than 550 g, yet still retained an excellent survival. This
may allow for the removal of the arbitrary age and tumor weight re-
strictions for S1 tumors, thereby expanding the number of patients able
to be treated with nephrectomy alone. S2 tumors (likewise common in
infants) had an excellent outcome in the current study (in which all
patients received adjuvant chemotherapy). In our previous study of
VLRWT, when such patients did not receive chemotherapy, there
was an increased risk of relapse [34,65], suggesting they may benefit
from chemotherapy. Therefore, these studies provide the opportunity
to define groups of VLRWT with different relapse risks using appropri-
ate biologic markers that are now being validated using samples from
the current protocol.
More globally, our findings illustrate that while pediatric embryo-
nal tumors have a restricted number of genetic events, they cannot be
characterized solely by activation of a single gene or pathway. Rather,
the clinical and biologic phenotype may be determined in part by the
developmental context in which genetic lesions are introduced. In
particular, our study highlights considerable complexity with regard
to the role ofWT1. The impact ofWT1 loss seems to change depend-
ing on the developmental timing and/or cell of origin of its occurrence,
as is seen in S2 and S3 tumors. We provide further evidence suggesting
that activation of key signaling pathways (NFAT, TGFB, Ras) is re-
stricted to those subsets arising through loss of WT1 expression quite
early in development (S2 and S4). Lastly, our study points toward
mechanisms of WT1 loss of expression other than mutation that need
to be identified. All these observations are of broad interest, as the crit-
ical role ofWT1 is increasingly demonstrated to play an important and
broad role in development and disease that extends well beyond the
kidney [46].
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Table W1. Top 100 Genes Differentially Expressed in Each Subset by GSEA.
S1 vs S5 S2 vs S5 S3 vs S5 S4 vs S5
Gene P FC Gene P FC Gene P FC Gene P FC
MGAM 2.7e − 10 12.7 MYH3 3.4e − 20 43.7 GAS2*,† 2.3e − 13 7.2 MYH3 2.3e − 06 11.4
KCNJ16 2.5e − 07 8.9 KBTBD10 4.2e − 16 34.0 MEOX2† 1.3e − 05 4.5 KBTBD10 7.4e − 05 10.4
HLA-DMA 7.2e − 09 20.2 TNNC1 9.3e − 17 39.7 SIM2*,† 2.7e − 12 4.5 TNNC1 2.0e − 05 8.8
GUCY1B3 7.9e − 12 10.9 TTN 2.8e − 17 25.1 NAV3*,† 1.6e − 13 4.3 TTN 2.5e − 05 10.0
AKR1C3 6.4e − 08 9.4 WIF1 1.7e − 11 19.2 EVI1† 1.8e − 05 3.5 ACTA1 1.9e − 04 9.8
IL1R1 8.8e − 09 16.5 ACTA1 2.9e − 14 21.2 NEF3* 3.5e − 05 2.8 TNNC2 3.0e − 05 8.0
AMIGO2 7.5e − 06 8.9 NEB 3.8e − 16 16.1 CNR1† 5.7e − 07 4.6 MYL1 2.5e − 05 8.0
TMEM23 1.6e − 08 6.1 TNNC2 4.2e − 12 23.3 WIF1*,† 5.3e − 04 3.1 NEB 1.9e − 05 4.9
FLJ20273 2.7e − 11 10.3 MYOZ2 3.6e − 10 13.5 GAD1*,† 6.0e − 05 4.9 ACTC1 1.2e − 06 8.6
FBLN2 2.9e − 09 13.6 MYOT 3.3e − 11 9.0 LMO2† 1.3e − 05 2.8 MEOX2 4.2e − 04 4.0
C11ORF32 5.2e − 07 11.0 MYL1 2.4e − 14 16.4 PLK2† 4.3e − 06 2.6 TPM2 6.3e − 06 5.5
SQRDL 1.7e − 10 8.4 OSR2 3.2e − 10 8.3 NPTX2† 4.1e − 07 2.7 EVI1 7.5e − 04 4.3
FRY 6.8e − 06 6.5 ACTC1 3.4e − 22 23.6 TGFB2† 2.2e − 05 2.7 WIF1 5.9e − 04 3.5
TNFSF10 3.6e − 04 7.0 TPM2 2.5e − 16 13.5 MID1*,† 5.5e − 09 2.8 GAS2 2.4e − 05 3.5
LGI1 1.0e − 03 11.9 DKK2 2.2e − 09 6.1 DKFZP686A01247† 2.2e − 07 2.6 MYLPF 9.1e − 06 5.5
HEY2 4.0e − 06 6.1 MYLPF 5.6e − 14 16.8 CXCR7† 2.0e − 04 2.1 NAV3 6.0e − 08 3.6
EGFL6 2.8e − 05 6.9 SULT1E1 5.5e − 08 8.6 TSPAN8† 8.6e − 04 2.0 COL15A1 3.1e − 03 4.7
ARHGAP29 1.4e − 06 7.5 TNNI1 3.0e − 12 9.2 RP6−213H19.1† 1.2e − 09 2.1 MYOZ2 4.4e − 03 3.8
C20ORF103 5.8e − 07 10.3 OGN 2.7e − 08 6.1 WNT5A*,† 4.1e − 04 3.0 CHODL 2.5e − 03 4.1
WISP3 1.4e − 06 4.7 CKM 1.3e − 08 8.9 NPY 2.1e − 03 2.9 CFH 3.8e − 04 2.9
BHLHB3 2.5e − 04 4.3 TWIST1 2.5e − 07 11.3 SART2† 1.1e − 06 2.5 OSR2 3.6e − 04 2.6
CLU 9.9e − 08 8.7 NEF3 6.0e − 15 4.9 EDNRA*,† 5.3e − 04 2.2 LUM 2.6e − 03 3.3
GRB14 1.5e − 04 4.5 LUM 2.3e − 20 6.7 BCHE† 1.2e − 02 2.6 MYOT 2.2e − 03 2.6
CLEC4M 5.2e − 05 7.8 TNNI2 2.5e − 09 9.6 CXCL6† 5.3e − 03 2.0 SRPX 7.7e − 03 5.4
CCND1 2.4e − 13 5.4 PITX2 3.8e − 08 3.9 FBN2† 1.1e − 05 2.0 BCHE 1.1e − 02 3.9
CLIC5 1.3e − 05 3.3 BCHE 1.5e − 07 4.6 CYP26A1† 3.0e − 05 2.2 MAL 2.4e − 03 2.9
CUGBP2 6.9e − 24 8.0 GAS2 2.6e − 11 5.2 CDH12 1.1e − 02 2.3 SPARCL1 1.1e − 04 3.6
FER1L3 1.8e − 06 5.5 TMEM47 4.2e − 08 5.4 LRRTM2† 5.2e − 03 2.0 PLSCR4 8.0e − 03 2.9
CTGF 1.1e − 10 6.1 FABP7 5.8e − 07 11.4 CCND1† 8.9e − 06 1.5 DLK1 5.8e − 04 2.3
CRTAC1 2.4e − 06 8.2 IL17B 1.6e − 10 4.8 PROM1† 9.7e − 09 1.7 EMX2 3.0e − 03 2.5
QPCT 5.6e − 05 4.1 DPT 1.1e − 08 8.9 GPR177*,† 3.5e − 07 2.1 SERPINF1 5.5e − 04 3.6
FGF14 7.9e − 07 4.3 NAV3 1.8e − 15 6.8 DNM3† 2.7e − 03 2.1 MATN2 7.1e − 03 3.1
OLFML2A 2.9e − 09 7.2 COL15A1 8.2e − 11 5.9 DKK1† 1.2e − 02 3.3 OGN 5.7e − 04 1.9
HS3ST2 2.8e − 09 6.2 COL21A1 5.1e − 09 5.3 EYA2† 1.7e − 04 1.9 ZFHX1B 3.6e − 03 2.3
PLOD2 4.5e − 14 5.8 MEF2C 8.7e − 13 6.6 LOXL1† 4.3e − 09 1.9 TNNI1 9.3e − 04 2.8
PPARGC1A 2.3e − 06 3.8 MYH8 2.0e − 12 7.6 IGF2BP3† 5.2e − 03 1.4 MEF2C 5.1e − 06 3.0
SATB2 3.2e − 05 3.5 DKK1 9.1e − 07 6.6 KIAA0960† 3.1e − 03 2.0 NEF3 4.3e − 03 2.3
SLC12A1 3.1e − 03 7.1 PLK2 3.8e − 17 4.8 IGFBP5† 1.2e − 06 1.9 CKM 5.6e − 04 2.6
C14ORF105 1.5e − 03 4.2 CHODL 1.2e − 09 5.2 RASL11B*,† 4.8e − 10 2.1 ALDH1A1 1.3e − 02 2.6
IRX5 5.2e − 05 3.6 ZFHX1B 8.7e − 09 3.3 LRIG1† 1.2e − 07 1.8 SIM2 4.0e − 03 3.3
GPX3 6.3e − 08 7.8 MYL4 1.9e − 11 5.2 IRX5† 1.0e − 04 1.4 COL21A1 6.1e − 03 2.6
ASTN2 8.8e − 06 4.7 DLK1 4.0e − 15 3.7 MYC† 2.5e − 05 1.6 PDGFRA 1.2e − 04 2.8
PDZD2 4.0e − 07 4.0 SERPINF1 1.4e − 17 5.1 EGFL6† 6.6e − 04 1.9 LDB2 1.1e − 04 2.5
TRHDE 1.5e − 03 3.8 EGFL6 2.1e − 09 4.3 CHGN† 5.0e − 04 1.9 CXCR7 1.3e − 03 2.2
LIFR 2.9e − 05 3.9 MEOX2 7.9e − 07 3.6 NEBL† 2.1e − 05 2.4 AGTR1 2.0e − 02 3.4
CD19 1.0e − 12 4.4 SPARCL1 7.5e − 18 5.2 DNAPTP6*,† 2.2e − 08 1.8 NFIB 5.4e − 03 3.0
SPOCK1 3.0e − 06 6.2 TPM3 2.6e − 07 4.2 KCNJ15† 7.0e − 05 1.9 FABP4 3.8e − 02 7.0
KRT8 7.6e − 09 4.3 TNNT2 1.3e − 07 3.6 PCOLCE*,† 1.7e − 06 1.9 DKFZP686A01247 2.4e − 04 2.5
CRYAB 2.2e − 06 4.3 PDGFRA 1.2e − 21 4.6 SATB2† 7.1e − 03 1.6 EDNRA 1.1e − 04 3.2
ADAMTS1 1.7e − 07 5.4 CXCL14 1.2e − 06 4.2 PCDH9† 1.8e − 03 1.9 TSPAN8 2.7e − 03 1.9
MEIS2 2.2e − 07 0.1 WT1 1.4e − 10 0.2 HAS2*,† 5.1e − 12 0.2 HAS2 1.3e − 04 0.3
LPHN2 1.1e − 07 0.2 KLK6 3.0e − 29 0.2 KLK6*,† 1.8e − 14 0.3 TMEM100 2.7e − 04 0.3
HMGA2 1.6e − 08 0.1 ITPR1 3.6e − 19 0.2 TMEM100† 2.8e − 09 0.2 TCEAL2 3.0e − 04 0.4
TCF21 9.1e − 07 0.2 ITGA8 8.2e − 15 0.2 WT1*,† 7.8e − 07 0.3 BMPER 4.0e − 06 0.4
PLAGL1 7.1e − 08 0.2 TMEM100 1.7e − 12 0.2 TCEAL2† 6.3e − 09 0.3 ZBTB10 1.4e − 04 0.5
CCND2 5.2e − 05 0.2 STAT4 7.6e − 30 0.2 ITGA8*,† 2.1e − 07 0.3 WT1 1.0e − 07 0.4
PLAG1 3.3e − 10 0.2 LYPD1 6.7e − 11 0.2 ITPR1*,† 2.2e − 10 0.3 STAT4 2.1e − 04 0.3
SIX2 7.9e − 07 0.2 BMPER 3.7e − 33 0.3 STAT4† 2.8e − 16 0.2 GPR64 2.2e − 03 0.4
POSTN 8.5e − 05 0.2 ADAMTS3 3.8e − 15 0.4 IFI16† 3.1e − 05 0.3 CD1D 3.7e − 15 0.4
HTR2B 1.9e − 06 0.2 WASF3 5.0e − 16 0.2 ADAMTS3*,† 1.1e − 08 0.5 TBL1XR1 3.9e − 03 0.5
CDH7 1.7e − 13 0.2 HAS2 1.5e − 13 0.3 FLRT3† 5.0e − 04 0.5 SLC7A11 4.2e − 08 0.3
TUBB2B 1.9e − 07 0.5 TCEAL2 1.2e − 08 0.3 KRT19† 4.0e − 03 0.8 BEX1 1.7e − 06 0.4
RHOBTB3 5.2e − 10 0.4 TCF21 1.3e − 07 0.4 PCTP*,† 1.0e − 11 0.5 CITED1 1.6e − 03 0.4
FZD2 3.0e − 06 0.2 KRT19 4.4e − 09 0.4 CITED1† 3.4e − 04 0.6 HTR2B 9.4e − 03 0.4
SNAI2 9.3e − 06 0.3 MEOX1 1.3e − 06 0.4 SLC7A11† 4.7e − 06 0.3 HOXC10 2.7e − 02 0.5
CHRNA1 6.6e − 14 0.3 NTRK2 4.2e − 09 0.3 HOXC6† 3.5e − 03 0.5 GCH1 1.7e − 03 0.5
FZD10 8.5e − 09 0.3 ID4 4.1e − 11 0.2 ADAMTS5† 3.1e − 04 0.5 ADAMTS3 6.3e − 03 0.6
LEF1 2.8e − 07 0.3 DBC1 4.4e − 23 0.3 PNMA2† 7.7e − 09 0.5 ITGA8 2.5e − 03 0.5
TMEM45A 3.7e − 07 0.3 FZD6 2.4e − 08 0.5 MMP23† 5.2e − 07 0.5 MEIS2 2.7e − 02 0.5
MEIS1 2.6e − 07 0.2 CD1D 1.6e − 18 0.4 GCH1† 1.6e − 03 0.6 KLK6 1.1e − 03 0.5
ELAVL4 3.2e − 24 0.3 SLC7A11 1.9e − 17 0.2 IL15† 2.4e − 11 0.6 ITPR1 3.7e − 03 0.5
ASPN 1.3e − 03 0.3 CDH7 1.4e − 13 0.4 WNT5B† 3.0e − 07 0.6 HOXD11 1.4e − 02 0.5
Table W1. (continued )
S1 vs S5 S2 vs S5 S3 vs S5 S4 vs S5
Gene P FC Gene P FC Gene P FC Gene P FC
IGF2BP3 2.2e − 10 0.1 ADCY2 8.9e − 19 0.3 MGAM† 1.4e − 09 0.5 SALL1 5.2e − 04 0.5
C3ORF52 1.5e − 24 0.3 FOXD1 4.1e − 06 0.4 HOXD1† 1.1e − 14 0.4 LYPD1 9.8e − 05 0.4
TRIM28 1.8e − 04 0.3 SPOCK2 8.2e − 14 0.3 WWP1† 5.9e − 08 0.5 MGC24039 1.5e − 06 0.6
COL6A3 1.2e − 05 0.2 FGFR2 1.8e − 16 0.4 PLVAP† 3.9e − 09 0.5 PBK 5.9e − 03 0.6
LRRTM2 2.0e − 10 0.3 HTR2B 1.4e − 04 0.4 PLCH1† 8.1e − 10 0.5 HOXD10 1.0e − 02 0.6
UCHL1 1.6e − 07 0.2 EYA1 5.5e − 08 0.4 BMPER† 4.3e − 05 0.5 C14ORF109 4.9e − 04 0.6
MMP23 1.8e − 09 0.3 ANKRD15 4.1e − 16 0.4 DUSP5† 3.8e − 14 0.5 PTPN14 2.2e − 05 0.6
DBC1 4.3e − 09 0.3 PTPN14 1.9e − 24 0.5 LYPD1*,† 4.5e − 06 0.4 ADCY2 1.2e − 05 0.5
VASH2 1.2e − 07 0.4 HOXD10 4.6e − 09 0.4 MEIS2† 8.6e − 03 0.6 HOXC6 7.0e − 02 0.6
C4ORF31 1.0e − 12 0.3 TACSTD1 2.0e − 07 0.4 RP11−301I17.1† 4.5e − 07 0.6 ANKRD6 6.1e − 04 0.6
PRAME 1.8e − 04 0.2 IL13RA1 9.9e − 13 0.4 DNM1† 3.0e − 09 0.5 CYP51A1 8.2e − 13 0.5
COL6A2 1.0e − 05 0.3 HOXD1 9.6e − 28 0.4 GRIK2† 1.3e − 06 0.5 NRXN1 3.5e − 09 0.6
SLC19A2 2.0e − 09 0.4 MMP23 8.9e − 12 0.5 ECEL1† 6.5e − 12 0.5 UTX 5.8e − 04 0.6
HOXA5 3.8e − 05 0.3 HOXD11 3.6e − 06 0.4 PON2*,† 7.5e − 08 0.5 SH3GLB2 3.2e − 04 0.6
SACS 1.1e − 16 0.4 LSR 1.2e − 08 0.5 WASF3*,† 7.8e − 08 0.5 DOCK4 3.9e − 04 0.6
BMPER 3.5e − 13 0.3 DUSP9 3.3e − 13 0.5 IL13RA1*,† 2.5e − 06 0.6 CLGN 3.1e − 04 0.6
ISLR 5.1e − 06 0.4 VAMP8 5.9e − 08 0.5 CD1D† 1.2e − 02 0.7 CDH7 1.7e − 03 0.6
TNC 2.3e − 07 0.5 DPP6 6.1e − 17 0.5 RAB27A† 5.9e − 11 0.5 MIR16 1.6e − 04 0.6
TTK 5.1e − 05 0.4 UNC5C 2.0e − 17 0.5 SPOCK2† 8.2e − 09 0.5 LOC63920 1.1e − 04 0.6
ANK2 2.3e − 06 0.4 CXXC4 1.7e − 14 0.5 GPR64† 7.4e − 03 0.6 FOXD1 2.3e − 03 0.5
GJA1 1.4e − 03 0.3 SALL1 4.9e − 06 0.5 FAM59A*,† 7.8e − 05 0.6 DBC1 7.2e − 04 0.5
LRRC17 1.2e − 06 0.4 MGAM 8.9e − 15 0.4 CYP51A1† 8.2e − 09 0.6 SMAD4 2.2e − 03 0.6
RP11-301I17.1 1.6e − 13 0.4 LAMA4 1.7e − 14 0.4 LPPR4† 2.3e − 08 0.6 MAK10 5.7e − 03 0.6
AHI1 1.1e − 06 0.4 PAX2 6.2e − 07 0.4 BCL2*,† 8.2e − 11 0.5 ZNF516 3.1e − 04 0.6
KIF26B 8.1e − 14 0.4 GCH1 1.4e − 06 0.5 HOXC10 3.4e − 02 0.7 KIF2A 6.2e − 05 0.6
PHLDA1 8.8e − 08 0.2 DSG2 1.0e − 08 0.5 ANKRD15† 6.3e − 06 0.6 IL15 1.3e − 06 0.6
ANKRD6 1.6e − 10 0.4 PLCB1 2.9e − 07 0.4 DLK1 1.8e − 03 0.3 PCTP 4.7e − 05 0.6
COL3A1 3.5e − 04 0.3 PCTP 7.1e − 17 0.5 S100A1† 6.1e − 05 0.6 HAT1 6.0e − 03 0.6
*PCC with WT1 > ±0.6.
†Also coordinately significantly (P < .001) differentially expressed in comparison S2 versus S5.
